- Home
- CGNT vs MLYS Comparison
CGNT vs MLYS Comparison
Compare CGNT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- MLYS
- Stock Information
- Founded
- CGNT 2020
- MLYS 2019
- Country
- CGNT Israel
- MLYS United States
- Employees
- CGNT N/A
- MLYS N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- CGNT Technology
- MLYS Health Care
- Exchange
- CGNT Nasdaq
- MLYS Nasdaq
- Market Cap
- CGNT 649.9M
- MLYS 526.1M
- IPO Year
- CGNT N/A
- MLYS 2023
- Fundamental
- Price
- CGNT $9.53
- MLYS $10.21
- Analyst Decision
- CGNT Hold
- MLYS Strong Buy
- Analyst Count
- CGNT 3
- MLYS 2
- Target Price
- CGNT $8.25
- MLYS $30.00
- AVG Volume (30 Days)
- CGNT 274.7K
- MLYS 263.5K
- Earning Date
- CGNT 12-11-2024
- MLYS 03-20-2025
- Dividend Yield
- CGNT N/A
- MLYS N/A
- EPS Growth
- CGNT N/A
- MLYS N/A
- EPS
- CGNT N/A
- MLYS N/A
- Revenue
- CGNT $339,818,000.00
- MLYS N/A
- Revenue This Year
- CGNT $13.67
- MLYS N/A
- Revenue Next Year
- CGNT $6.92
- MLYS N/A
- P/E Ratio
- CGNT N/A
- MLYS N/A
- Revenue Growth
- CGNT 12.16
- MLYS N/A
- 52 Week Low
- CGNT $6.21
- MLYS $8.58
- 52 Week High
- CGNT $9.97
- MLYS $16.91
- Technical
- Relative Strength Index (RSI)
- CGNT 58.56
- MLYS 44.53
- Support Level
- CGNT $8.92
- MLYS $9.57
- Resistance Level
- CGNT $9.55
- MLYS $10.79
- Average True Range (ATR)
- CGNT 0.41
- MLYS 0.64
- MACD
- CGNT -0.03
- MLYS 0.11
- Stochastic Oscillator
- CGNT 61.87
- MLYS 63.98
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.